FI3723739T3 - Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi - Google Patents
Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi Download PDFInfo
- Publication number
- FI3723739T3 FI3723739T3 FIEP18889875.3T FI18889875T FI3723739T3 FI 3723739 T3 FI3723739 T3 FI 3723739T3 FI 18889875 T FI18889875 T FI 18889875T FI 3723739 T3 FI3723739 T3 FI 3723739T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- ophthalmic
- isoxazoline
- parasiticide
- use according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 29
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 title claims 24
- 230000000590 parasiticidal effect Effects 0.000 title claims 14
- 239000002297 parasiticide Substances 0.000 title claims 14
- 208000010217 blepharitis Diseases 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 230000002141 anti-parasite Effects 0.000 claims 8
- 239000003096 antiparasitic agent Substances 0.000 claims 8
- 241001128004 Demodex Species 0.000 claims 4
- HDKWFBCPLKNOCK-SFHVURJKSA-N 3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5s)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)NCC(=O)NCC(F)(F)F)=C(C)C=C1C1=NO[C@](C(F)(F)F)(C=2C=C(Cl)C(Cl)=C(Cl)C=2)C1 HDKWFBCPLKNOCK-SFHVURJKSA-N 0.000 claims 3
- 208000030852 Parasitic disease Diseases 0.000 claims 3
- 210000001508 eye Anatomy 0.000 claims 3
- 229950002303 lotilaner Drugs 0.000 claims 3
- 239000003889 eye drop Substances 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 210000000720 eyelash Anatomy 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi silmän Demodex-loistartunnan hoitamisessa ihmispotilaassa, jossa oftalminen isoksatsoliiniloislääkekoostumus on silmätipan muo- dossa, jossa oftalminen isoksatsoliiniloislääkekoostumus käsittää farmaseut- tisesti hyväksyttävää vehikkeliä, ja jossa oftalminen koostumus on tarkoitus annostella ulkoisesti yhteen tai useampaan seuraavista: potilaan silmään, silmäluomiin tai silmäripsiin.
2. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi patentti- vaatimuksen 1 mukaisesti, jossa ihmispotilaaseen on tarkoitus annostella 0,01 % - 1 % isoksatsoliiniloislääkettä koostumuksen kokonaispainon suhteen.
3. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi patentti- vaatimuksen 1 tai patenttivaatimuksen 2 mukaisesti, jossa ihmispotilaaseen on — tarkoitus annostella 0,25 painoprosenttia isoksatsoliiniloislääkettä koostumuksen kokonaispainon suhteen.
4. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi patentti- vaatimuksen 1 tai patenttivaatimuksen 2 mukaisesti, jossa isoksatsoliiniloislääke on valittu ryhmästä, joka koostuu fluralaneerista, sarolaneerista, lotilaneerista, afoksolaneerista ja fluksametamidista.
5. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi patentti- vaatimuksen 4 mukaisesti, jossa isoksatsoliiniloislääke käsittää lotilaneeria.
6. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi minkä ta- hansa edellä olevan patenttivaatimuksen mukaisesti, jossa oftalminen koostumus — ei sisällä eteerisiä öljyjä.
7. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi minkä ta- hansa edellä olevan patenttivaatimuksen mukaisesti, jossa silmän Demodex-lois- tartunta käsittää Demodex-silmäluomitulehduksen.
8. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi minkä ta- hansa edellä olevan patenttivaatimuksen mukaisesti, jossa silmän Demodex-lois- tartunta sijaitsee luomitukirauhasissa.
9. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi minkä ta- hansa edellä olevan patenttivaatimuksen mukaisesti, jossa isoksatsoliiniloislääke on oftalmisen koostumuksen ainoa vaikuttava ainesosa.
10. Oftalminen isoksatsoliiniloislääkekoostumus käytettäväksi minkä tahansa edellä olevan patenttivaatimuksen mukaisesti, jossa oftalmista koostumusta on tarkoitus antaa ulkoisesti ainakin kerran päivässä ainakin neljän viikon ajan.
11. Oftalminen isoksatsoliiniloislääkekoostumus, jossa oftalminen isoksatsoliiniloislääkekoostumus on silmätipan muo- dossa, jossa oftalminen koostumus käsittää 0,25 painoprosenttia isoksatsolii- niloislääkettä koostumuksen kokonaispainon suhteen, jossa oftalminen koostumus käsittää farmaseuttisesti hyväksyttävää vehikkeliä, ja jossa oftalminen koostumus on steriiliä.
12. Patenttivaatimuksen 11 mukainen oftalminen isoksatsoliiniloislää- kekoostumus, jossa isoksatsoliiniloislääke on valittu ryhmästä, joka koostuu flura- laneerista, sarolaneerista, lotilaneerista, afoksolaneerista ja fluksametamidista.
13. Patenttivaatimuksen 11 mukainen oftalminen isoksatsoliiniloislää- kekoostumus, jossa koostumus on öljypohjainen, ja jossa koostumus käsittää yhtä tai useampaa seuraavista: mineraaliöljyä, risiiniöljyä tai vaseliinia.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762599213P | 2017-12-15 | 2017-12-15 | |
US201862615855P | 2018-01-10 | 2018-01-10 | |
US201862626612P | 2018-02-05 | 2018-02-05 | |
US201862689787P | 2018-06-25 | 2018-06-25 | |
US201862746498P | 2018-10-16 | 2018-10-16 | |
PCT/US2018/065849 WO2019118928A1 (en) | 2017-12-15 | 2018-12-14 | Isoxazoline parasiticide formulations and methods for treating blepharitis |
Publications (1)
Publication Number | Publication Date |
---|---|
FI3723739T3 true FI3723739T3 (fi) | 2024-06-19 |
Family
ID=66814591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FIEP18889875.3T FI3723739T3 (fi) | 2017-12-15 | 2018-12-14 | Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi |
Country Status (15)
Country | Link |
---|---|
US (10) | US10835517B2 (fi) |
EP (2) | EP3723739B1 (fi) |
JP (2) | JP2021506971A (fi) |
KR (1) | KR20200111177A (fi) |
CN (1) | CN111655241A (fi) |
AU (2) | AU2018385766B2 (fi) |
BR (1) | BR112020012018A2 (fi) |
CA (1) | CA3085787A1 (fi) |
DK (1) | DK3723739T3 (fi) |
FI (1) | FI3723739T3 (fi) |
IL (2) | IL275339B2 (fi) |
MX (1) | MX2020006309A (fi) |
RU (1) | RU2020122841A (fi) |
WO (1) | WO2019118928A1 (fi) |
ZA (1) | ZA202004155B (fi) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020012018A2 (pt) | 2017-12-15 | 2020-11-24 | Tarsus Pharmaceuticals, Inc. | formulações de parasiticida de isoxazolina e métodos para tratar blefarite |
US10730901B2 (en) | 2018-07-27 | 2020-08-04 | Aperta Biosciences, Llc | Spinosyn formulations for treatment of demodex-induced ocular and facial conditions |
EP3986377A4 (en) * | 2019-06-19 | 2023-07-19 | Tarsus Pharmaceuticals, Inc. | ISOXAZOLINE PARASITICIDAL FORMULATIONS AND METHODS OF TREATING BLEPHARITIS |
WO2023205459A1 (en) * | 2022-04-22 | 2023-10-26 | Attillaps Holdings Inc. | Anticholinergic agents and muscarinic agonists for the treatment of demodex related conditions |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2361974A (en) | 1940-02-07 | 1944-11-07 | John A Rietmann | Electrolytic cell |
US3781355A (en) | 1969-12-12 | 1973-12-25 | Boots Pure Drug Co Ltd | Pesticidal compounds and compositions |
US3864497A (en) | 1970-12-01 | 1975-02-04 | Boots Pure Drug Co Ltd | Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener |
US4389397A (en) | 1980-08-04 | 1983-06-21 | Merck & Co., Inc. | Solubilization of ivermectin in water |
US5019392A (en) | 1988-03-03 | 1991-05-28 | Micro-Pak, Inc. | Encapsulation of parasiticides |
US5614545A (en) | 1988-06-09 | 1997-03-25 | Leonard Bloom | Topical composition for treatment of blepharitis |
US4957918A (en) | 1988-06-09 | 1990-09-18 | Leonard Bloom | Topical treatment of blepharitis |
US6001822A (en) | 1989-04-11 | 1999-12-14 | Pfizer Inc. | Antiparasitic formulations |
FR2656526B1 (fr) | 1990-01-02 | 1994-10-28 | Virbac Sa Laboratoires | Dispositif a liberation controlee et procede de preparation. |
WO1994015597A1 (en) | 1993-01-11 | 1994-07-21 | Allergan, Inc. | Ophthalmic compositions comprising benzyllauryldimethylammonium chloride |
US5632999A (en) | 1993-08-18 | 1997-05-27 | Virbac, Inc. | Sustained release pyriproxifen compositions for parasite control |
US5981500A (en) | 1994-01-12 | 1999-11-09 | Pfizer Inc. | Antiparasitic agents related to the milbemycins and avermectins |
FR2729539B1 (fr) | 1995-01-23 | 1997-04-11 | Virbac Lab | Dispositif a liberation controlee de substances chimiques, destine a etre fixe sur un animal et procede de preparation dudit dispositif |
DE19613972A1 (de) | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
RU2126668C1 (ru) | 1996-10-17 | 1999-02-27 | Багров Сергей Николаевич | Мазь для лечения блефаритов "демалон" |
FR2761886B1 (fr) | 1997-04-14 | 2000-05-05 | Virbac Sa | Compositions contenant au moins un polymere cationique et au moins une molecule active contenue dans au moins un vecteur micro ou nanoparticulaire, et leur utilisation pour le traitement de surfaces vivantes ou inertes |
US5968990A (en) | 1997-10-14 | 1999-10-19 | Isp Investments Inc. | Water-dilutable, microemulsion concentrate and pour-on formulations thereof |
US6255350B1 (en) | 1997-10-14 | 2001-07-03 | Isp Investments Inc. | Stabilized concentrates of water unstable AZA compounds and o/w miniemulsions thereof |
US6455583B1 (en) | 1998-05-08 | 2002-09-24 | The University Of Miami | Method for treating meibomian gland disease |
US5952372A (en) | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
GB9825402D0 (en) | 1998-11-19 | 1999-01-13 | Pfizer Ltd | Antiparasitic formulations |
US7897559B2 (en) | 2000-06-29 | 2011-03-01 | Parks L Dean | Dermatological composition and kit containing avermectin compound for treating dermatological conditions |
US6696067B2 (en) | 2001-04-12 | 2004-02-24 | Ondeo Nalco Company | Cosmetic compositions containing dispersion polymers |
US6881726B2 (en) | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
IL147921A0 (en) | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
AU2003215011A1 (en) | 2002-02-08 | 2003-09-02 | Mcneil-Ppc, Inc. | Topical ivermectin composition |
US7906128B2 (en) | 2002-10-21 | 2011-03-15 | Wyeth Llc | Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
MXPA05011208A (es) | 2003-04-24 | 2005-12-14 | Galderma Sa | Uso de ivermectina para el tratamiento de desordenes dermatologicos. |
FR2854074B1 (fr) | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
US7531186B2 (en) | 2003-12-17 | 2009-05-12 | Merial Limited | Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz |
EA014881B1 (ru) | 2004-03-05 | 2011-02-28 | Ниссан Кемикал Индастриз, Лтд. | Производные замещенного алкилбензола |
US8568794B2 (en) | 2004-03-12 | 2013-10-29 | Life Science Investments, Ltd. | Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassinoid-containing plant extracts |
US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
TWI350728B (en) | 2004-10-08 | 2011-10-21 | Wyeth Corp | Amitraz compositions |
WO2006040688A2 (en) | 2004-10-12 | 2006-04-20 | Ernir Snorrason | Inhibitors of acetylcholinesterase for treating skin diseases |
GB2419093A (en) | 2004-10-12 | 2006-04-19 | Ernir Snorrason | Acetylcholinesterase inhibitors for the treatment of skin |
AU2005304034B2 (en) | 2004-11-09 | 2012-02-16 | Santen Sas | Ophthalmic emulsions containing an immunosuppressive agent |
DE102004053964A1 (de) | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Mittel gegen Demodikose |
US20090214676A1 (en) | 2005-04-30 | 2009-08-27 | Tissuetech, Inc. | Method for treating ocular demodex |
FR2886851B1 (fr) | 2005-06-10 | 2007-10-05 | Galderma Sa | Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee |
EP1932836B1 (en) | 2005-09-02 | 2013-11-06 | Nissan Chemical Industries, Ltd. | Isoxazoline-substituted benzamide compound and harmful organism-controlling agent |
FR2891460B1 (fr) | 2005-09-30 | 2010-07-30 | Galderma Sa | Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. |
EP1965645A2 (en) | 2005-12-14 | 2008-09-10 | E.I. Du Pont De Nemours And Company | Isoxazolines for controlling invertebrate pests |
TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
FR2900052B1 (fr) | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
MX2008013307A (es) | 2006-04-20 | 2008-10-27 | Du Pont | Pirazolinas para controlar plagas de invertebrados. |
JP2008044880A (ja) | 2006-08-15 | 2008-02-28 | Bayer Cropscience Ag | 殺虫性イソオキサゾリン類 |
JP5256753B2 (ja) | 2007-03-29 | 2013-08-07 | 住友化学株式会社 | イソオキサゾリン化合物とその有害生物防除用途 |
WO2008122375A2 (en) | 2007-04-10 | 2008-10-16 | Bayer Cropscience Ag | Insecticidal aryl isoxazoline derivatives |
CA2686766A1 (en) * | 2007-05-09 | 2008-11-20 | Ganial Immunoterapeutics Inc. | (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent |
BRPI0809770B8 (pt) | 2007-06-13 | 2022-12-06 | Du Pont | Composto e composição para controlar uma praga de invertebrados |
TWI556741B (zh) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
US8128968B2 (en) | 2007-08-29 | 2012-03-06 | Tissuetech, Inc. | Compositions and methods for treating Demodex infestations |
WO2009045999A1 (en) | 2007-10-03 | 2009-04-09 | E. I. Du Pont De Nemours And Company | Naphthalene isoxazoline compounds for control of invertebrate pests |
FR2922108A1 (fr) | 2007-10-11 | 2009-04-17 | Virbac Sa | Utilisation d'un derive de 1-n-(halo-3-pyridylmethyle)-n-methylamino-1-alkylamino -2- nitroethylene pour la preparation d'une composition pharmaceutique veterinaire pour lutter contre les puces |
FR2925337B1 (fr) | 2007-12-21 | 2010-01-15 | Virbac | Composition pharmaceutique contenant un derive de n-phenylpyrazole et du glycofurol, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces |
US20110059925A1 (en) | 2008-03-26 | 2011-03-10 | Eric Donnenfeld | Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics |
JP2011527307A (ja) | 2008-07-09 | 2011-10-27 | ビーエーエスエフ ソシエタス・ヨーロピア | イソオキサゾリン化合物iを含む殺有害生物活性混合物 |
EP2308857B1 (en) | 2008-07-09 | 2016-04-27 | Nissan Chemical Industries, Ltd. | Process for production of isoxazoline-substituted benzoic acid amide compound |
WO2010059529A2 (en) | 2008-11-19 | 2010-05-27 | Merial Limited | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
US9173728B2 (en) | 2008-11-19 | 2015-11-03 | Merial Inc. | Multi-cavity container having offset indentures for dispensing fluids |
EP2567618B1 (fr) | 2008-12-16 | 2017-05-03 | Virbac | Composition pharmaceutique contenant un dérivé de N-phénylpyrazole, utilisation pour la préparation d'un médicament vétérinaire topique pour lutter contre les puces |
NZ593135A (en) | 2008-12-19 | 2013-04-26 | Novartis Ag | Isoxazoline derivatives and their use as pesticide |
US8313752B2 (en) | 2009-04-14 | 2012-11-20 | Merial Limited | Macrocyclic lactone combination compositions, vaccines and methods for producing same |
FR2945797B1 (fr) | 2009-05-20 | 2015-11-06 | Virbac Sa | Conditionnement alimentaire,pharmaceutique ou veterinaire de securite et son procede de fabrication |
CA2790682C (en) | 2010-03-03 | 2020-11-24 | Neocutis Sa | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
US10238102B2 (en) | 2010-04-12 | 2019-03-26 | Exosect Limited | Control of arthropods in animal environments |
US8211450B2 (en) | 2010-05-05 | 2012-07-03 | Senju Usa, Inc. | Ophthalmic composition |
CN102260252A (zh) * | 2010-05-24 | 2011-11-30 | 盟科医药技术(上海)有限公司 | 可用于治疗细菌感染的新噁唑烷酮 |
EP2654757A1 (en) * | 2010-12-22 | 2013-10-30 | Entarco SA | The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents |
BR112013015503A2 (pt) | 2010-12-27 | 2017-06-27 | Intervet Int Bv | formulação localizada tópica, uso de uma formulação, e, método para tratamento ou profilaxia de infestação de parasita de um animal |
US20130331768A1 (en) | 2010-12-29 | 2013-12-12 | Louis D. Nichamin | Eye treatment |
AU2012215440B2 (en) | 2011-02-10 | 2015-08-27 | Novartis Tiergesundheit Ag | Isoxazoline derivatives for controlling invertebrate pests |
JP5806743B2 (ja) | 2011-03-10 | 2015-11-10 | ゾエティス・エルエルシー | 抗寄生虫薬としてのスピロ環式イソオキサゾリン誘導体 |
PL2755473T3 (pl) * | 2011-09-12 | 2019-05-31 | Merial Inc | Kompozycje przeciwpasożytniczne zawierające izoksazolinową substancję czynną, sposoby i ich zastosowania |
CN102552114A (zh) | 2012-03-19 | 2012-07-11 | 段亚东 | 甲硝唑眼用凝胶及其制备方法和用途 |
US9345522B2 (en) | 2012-05-22 | 2016-05-24 | Matthew Songer | Bone fixation screw and method |
AU2013308887B2 (en) | 2012-08-31 | 2015-11-12 | Zoetis Services Llc | Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone |
US9095566B1 (en) | 2013-06-28 | 2015-08-04 | Edward Quicksilver Yavitz | Eyelash and eyelid margin infections |
US9233117B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S. A. | Treatment of inflammatory lesions of rosacea with ivermectin |
WO2019126541A1 (en) | 2017-12-20 | 2019-06-27 | Attillaps Holdings | Treatment of ophthalmological conditions with acetylcholinesterase inhibitors |
WO2015017328A2 (en) | 2013-07-29 | 2015-02-05 | Spallitta Frank Anthony | Organophosphates for treating afflictions of the skin |
EP3082867B1 (en) * | 2013-12-20 | 2024-01-17 | Intervet International B.V. | Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals |
WO2015183799A1 (en) | 2014-05-28 | 2015-12-03 | Macular Health, Llc | Ocular eyelid scrub composition for the treatment of demodex blepharitis |
PT3157534T (pt) | 2014-06-19 | 2022-08-04 | Attillaps Holdings | Inibidores de acetilcolinestérase para o tratamento de condições da dermatológicas |
WO2016022066A1 (en) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
CN106999475B (zh) * | 2014-12-22 | 2022-10-25 | 英特维特国际股份有限公司 | 异噁唑啉化合物用于治疗蠕形螨病的用途 |
EP3261620B1 (en) * | 2015-02-24 | 2022-11-09 | The Board of Trustees of the University of Illinois | Methods and compositions for treating dry eye disease and other eye disorders |
UY36570A (es) | 2015-02-26 | 2016-10-31 | Merial Inc | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas |
US20160287566A1 (en) | 2015-04-04 | 2016-10-06 | Thomas Lynn Busby | Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals |
CN107750159B (zh) | 2015-06-23 | 2021-10-29 | 英特维特国际股份有限公司 | 用于消毒的饮用水的含有维生素的异噁唑啉溶液 |
US20170024748A1 (en) | 2015-07-22 | 2017-01-26 | Patient Doctor Technologies, Inc. | Guided discussion platform for multiple parties |
CN108137529A (zh) * | 2015-09-03 | 2018-06-08 | 阿格里麦蒂斯有限责任公司 | 作为杀虫剂的多杀菌素衍生物 |
NZ739853A (en) | 2015-09-10 | 2018-11-30 | Dow Agrosciences Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
KR20180090251A (ko) | 2015-09-28 | 2018-08-10 | 아주라 오프탈믹스 엘티디 | 마이봄샘 지질 분비를 증가시키기 위한 티올 및 이황화물 함유 약제 |
UY37137A (es) * | 2016-02-24 | 2017-09-29 | Merial Inc | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos |
WO2017176948A1 (en) | 2016-04-06 | 2017-10-12 | Merial, Inc. | Process for the preparation of enantiomerically enriched isoxazoline compounds - crystalline toluene solvate of (s)-afoxolaner |
ES2953467T3 (es) | 2016-04-15 | 2023-11-13 | Elanco Animal Health Gmbh | Derivados de pirazolopirimidina |
EP3532041A4 (en) | 2016-10-31 | 2020-06-24 | The Scripps Research Institute | METHOD AND COMPOSITIONS FOR PREVENTING VECTOR-INDUCED DISEASE TRANSMISSION |
BR112020012018A2 (pt) * | 2017-12-15 | 2020-11-24 | Tarsus Pharmaceuticals, Inc. | formulações de parasiticida de isoxazolina e métodos para tratar blefarite |
US10730901B2 (en) | 2018-07-27 | 2020-08-04 | Aperta Biosciences, Llc | Spinosyn formulations for treatment of demodex-induced ocular and facial conditions |
AU2020251960A1 (en) | 2019-04-04 | 2021-11-11 | Tarsus Pharmaceuticals, Inc. | Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis |
US20220249445A1 (en) | 2019-06-19 | 2022-08-11 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
-
2018
- 2018-12-14 BR BR112020012018-9A patent/BR112020012018A2/pt unknown
- 2018-12-14 CN CN201880088176.3A patent/CN111655241A/zh active Pending
- 2018-12-14 DK DK18889875.3T patent/DK3723739T3/da active
- 2018-12-14 RU RU2020122841A patent/RU2020122841A/ru unknown
- 2018-12-14 KR KR1020207020368A patent/KR20200111177A/ko not_active Application Discontinuation
- 2018-12-14 US US16/221,390 patent/US10835517B2/en active Active
- 2018-12-14 EP EP18889875.3A patent/EP3723739B1/en active Active
- 2018-12-14 MX MX2020006309A patent/MX2020006309A/es unknown
- 2018-12-14 EP EP24158453.1A patent/EP4397375A2/en active Pending
- 2018-12-14 IL IL275339A patent/IL275339B2/en unknown
- 2018-12-14 AU AU2018385766A patent/AU2018385766B2/en active Active
- 2018-12-14 JP JP2020552674A patent/JP2021506971A/ja active Pending
- 2018-12-14 FI FIEP18889875.3T patent/FI3723739T3/fi active
- 2018-12-14 CA CA3085787A patent/CA3085787A1/en active Pending
- 2018-12-14 WO PCT/US2018/065849 patent/WO2019118928A1/en unknown
- 2018-12-14 IL IL307992A patent/IL307992A/en unknown
-
2020
- 2020-07-07 ZA ZA2020/04155A patent/ZA202004155B/en unknown
- 2020-11-16 US US17/099,531 patent/US20210077465A1/en active Pending
- 2020-11-16 US US17/099,570 patent/US20220054457A2/en not_active Abandoned
-
2021
- 2021-03-05 US US17/193,453 patent/US11197847B2/en active Active
-
2022
- 2022-07-26 US US17/873,698 patent/US11752137B2/en active Active
- 2022-07-26 US US17/873,540 patent/US11690826B2/en active Active
- 2022-07-26 US US17/873,548 patent/US11690827B2/en active Active
-
2023
- 2023-02-15 AU AU2023200843A patent/AU2023200843A1/en active Pending
- 2023-02-15 US US18/169,553 patent/US20230190711A1/en active Pending
- 2023-05-30 US US18/325,910 patent/US20230301971A1/en active Pending
- 2023-05-30 US US18/325,919 patent/US20230293496A1/en active Pending
-
2024
- 2024-01-19 JP JP2024006895A patent/JP2024038449A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI3723739T3 (fi) | Isoksatsoliiniloislääkeformulaatioita ja niiden käyttö silmäluomitulehduksen hoitamiseksi | |
KR102614858B1 (ko) | 안검염 치료에 사용되는 약제학적 조성물 | |
CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
CA3045733A1 (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
BRPI0608152A2 (pt) | formulações para tratamento ocular | |
BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
RU2017129247A (ru) | Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний | |
MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
MX356343B (es) | Compuestos que inhiben la exocitosis neuronal (ii). | |
Mandal et al. | Drugs–do we need them? Applications of non-pharmaceutical therapy in anterior eye disease: a review | |
WO2016060917A3 (en) | Formulations for histatin therapeutics | |
WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
BR112023006371A2 (pt) | Composição oftalmológica tópica | |
WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
BR112018072647A2 (pt) | composições oftálmicas | |
JP7191022B2 (ja) | アルカフタジン又はその塩を含有する水性医薬組成物 | |
BR112017014379A2 (pt) | composição para o tratamento de infecções causadas pelo acaro demodex spp | |
MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
JP2016511246A (ja) | 局所眼用鎮痛薬 | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
ES2779525T3 (es) | Composición que comprende un éster de alfa-tocoferol para prevención y tratamiento de rinitis alérgica | |
Sato et al. | Relative potency of tyrosol in the treatment of endotoxin-induced uveitis in rats | |
RU2537242C1 (ru) | Ректальные суппозитории с никотиновой кислотой и экстрактом прополиса | |
NZ766141B2 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
RU2561049C1 (ru) | Офтальмологическая композиция в виде капель для лечения инфекционно-воспалительных заболеваний глаз, устойчивых к антибиотикам. |